The real-world efficacy and safety of nivolumab plus chemotherapy in patients with HER2-negative advanced gastric cancer

zu Verbundenen Objekten

Standort
Deutsche Nationalbibliothek Frankfurt am Main
Umfang
1 Online-Ressource.
Sprache
Englisch

Erschienen in
The real-world efficacy and safety of nivolumab plus chemotherapy in patients with HER2-negative advanced gastric cancer ; volume:24 ; number:1 ; day:28 ; month:10 ; year:2024 ; pages:1-10 ; date:12.2024
BMC cancer ; 24, Heft 1 (28.10.2024), 1-10, 12.2024

Urheber
Liu, Yu-Yin
Tsai, Ming-Yen
Liu, Ting-Ting
Liu, Yueh-Wei
Lin, Yu-Hung
Yeh, Cheng-Hsi
Lin, Yu-Cheng
Chen, Yen-Hao
Beteiligte Personen und Organisationen
SpringerLink (Online service)

DOI
10.1186/s12885-024-13066-z
URN
urn:nbn:de:101:1-2501172135510.914359116098
Rechteinformation
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
Letzte Aktualisierung
15.08.2025, 07:33 MESZ

Datenpartner

Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Original beim Datenpartner anzeigen

Beteiligte

  • Liu, Yu-Yin
  • Tsai, Ming-Yen
  • Liu, Ting-Ting
  • Liu, Yueh-Wei
  • Lin, Yu-Hung
  • Yeh, Cheng-Hsi
  • Lin, Yu-Cheng
  • Chen, Yen-Hao
  • SpringerLink (Online service)

Ähnliche Objekte (12)

Perioperative chemotherapy with nivolumab for HER2-negative locally advanced gastric cancer: a case series

Perioperative chemotherapy with nivolumab for HER2-negative locally advanced gastric cancer: a case series

The impact of HER2-low status on response to neoadjuvant chemotherapy in clinically HER2-negative breast cancer

The impact of HER2-low status on response to neoadjuvant chemotherapy in clinically HER2-negative breast cancer

21-Gene assay as predictor of chemotherapy benefit in HER2-negative breast cancer

21-Gene assay as predictor of chemotherapy benefit in HER2-negative breast cancer

Ki67 expression and the effect of neo-adjuvant chemotherapy on luminal HER2-negative breast cancer

Ki67 expression and the effect of neo-adjuvant chemotherapy on luminal HER2-negative breast cancer

Eribulin plus carboplatin combination for HER2-negative metastatic breast cancer: a multicenter, real-world cohort study

Eribulin plus carboplatin combination for HER2-negative metastatic breast cancer: a multicenter, real-world cohort study

New HER2-negative breast cancer subtype responsive to anti-HER2 therapy identified

New HER2-negative breast cancer subtype responsive to anti-HER2 therapy identified

Immunotherapy for hormone receptor‒positive HER2-negative breast cancer

Immunotherapy for hormone receptor‒positive HER2-negative breast cancer

Palbociclib and letrozole for hormone receptor-positive HER2-negative breast cancer with residual disease after neoadjuvant chemotherapy

Palbociclib and letrozole for hormone receptor-positive HER2-negative breast cancer with residual disease after neoadjuvant chemotherapy

Real-world data on neoadjuvant chemotherapy with dual-anti HER2 therapy in HER2 positive breast cancer

Real-world data on neoadjuvant chemotherapy with dual-anti HER2 therapy in HER2 positive breast cancer

HER2-low breast cancer shows a lower immune response compared to HER2-negative cases

HER2-low breast cancer shows a lower immune response compared to HER2-negative cases

Phase Ib/II study of nivolumab combined with palliative radiation therapy for bone metastasis in patients with HER2-negative metastatic breast cancer

Phase Ib/II study of nivolumab combined with palliative radiation therapy for bone metastasis in patients with HER2-negative metastatic breast cancer

Survival is associated with complete response on MRI after neoadjuvant chemotherapy in ER-positive HER2-negative breast cancer

Survival is associated with complete response on MRI after neoadjuvant chemotherapy in ER-positive HER2-negative breast cancer

Verbundene Objekte